Australia reimburses deferred medicines
This article was originally published in Scrip
Australia's health ministry has listed six of the eight drugs deferred for listing on the state-funded Pharmaceutical Benefits Scheme (PBS). The government has also promised not to defer drugs that would cost the system less than A$10 million a year. The R&D-based pharmaceutical association, Medicines Australia, has welcomed the developments, but says more must be done to deal with the deferrals issue properly.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.